PILRA, Recombinant, Human, aa20-196 (FDF03, PILR-alpha, Paired Immunoglobulin-like Type 2 Receptor-alpha)
Catalog No : USB-145827
682.78€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | PILRA, Recombinant, Human, aa20-196 (FDF03, PILR-alpha, Paired Immunoglobulin-like Type 2 Receptor-alpha) | ||
|---|---|---|---|
| Catalog No | USB-145827 | ||
| Supplier’s Catalog No | 145827 | ||
| Supplier | US Biologicals | ||
| Source antigen | Recombinant, NS0 cells | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 3340 | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Highly Purified | ||
| Purity | ~95% (SDS-PAGE) | ||
| Form | Supplied as a lyophilized powder in PBS, EDTA. BSA free. Reconstitute with 500ul sterile PBS. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | ~95% (SDS-PAGE) | ||
| Description | PILRalpha (paired immunoglobulinlike type 2 receptoralpha; also FDF03) is one of two members that belong to a small family of immunoregulatory Igsuperfamily receptors (14). It is a counterpart to PILRbeta, and likely gave rise to the PILRbeta gene through duplication and rearrangement (1). The PILRs represent one of many pairs of Iglike domaincontaining receptors that participate in immune regulation. PILRalpha and beta should not be confused with the similarly named PIRs (also paired immunoglobulinlike receptors ), or the functionallyrelated SIRP and ILT/LILR/CD85/LIR family of receptors (2). While PIRs, ILTs and SIRPs contain three to six Iglike domains in their extracellular region, PILRalpha and beta show only one Iglike region in their extracellular domain (ECD) (15). Human PILRalpha is a monomeric, 55kD, 294 amino acid (aa) type I transmembrane (TM) glycoprotein (35). It contains a 178 aa ECD (aa 20197), a 21 aa TM segment, and a long, 85 aa cytoplasmic region (aa 219303). The ECD shows one Vtype Iglike domain between aa 32150, while the cytoplasmic region contains two ITIMs (immunoreceptor Tyrbased inhibitory motifs) between aa 267272 and 296301. Given that ITIMs are known to interact with phosphatases such as PTPN6 and PTPN11, the presence of these motifs make mouse PILRalpha an inhibitory receptor. Three potential isoforms for human PILRalpha have been reported. The first contains a 24 aa substitution for aa 152303, a second possesses a 36 aa substitution for aa 264303, and a third shows a deletion of aa 152224 (6). The human PILRalpha ECD shares 43% aa sequence identity with mouse PILRalpha ECD, and 82% aa sequence identity with the ECD of human PILRbeta (3, 4). PILRalpha is expressed by neutrophils, macrophages, monocytes, mast cells, APCs, microglia, neurons, cardiac muscle and renal proximal plus pancreatic duct eipthelium (4, 7, 8). It has multiple binding partners, including CD99 (4, 9), glycoprotein B/gB of HSV1 (7), PANP (PILRassociated neural protein) (8) and NPDC1 plus collectin12 (10). Although PILRalpha and beta are related through gene duplication and highly similar in their ECD aa sequence, they do not necessarily share the same ligands (or binding partners), as PILRbeta fails to bind to gB and PANP (8, 10). Notably, PILRalpha binding appears to be dependent upon the presence of a poorlydefined peptide sequence coupled to a sialylated, Olinked carbohydrate motif (5, 912). It is unclear what function(s) can be attributed to PILRalpha. One possibility suggests that in the early stage of an immune response, PILRbeta predominates over PILRalpha on the APC surface. Ligation of PILRbeta by CD99 induces IL12 production and immune cell activation. But this ligation also upregulates PILRalpha expression, and subsequent CD99:PILRalpha engagement now promotes IL27 production, with a concomitant increase in T cell IL10 production, and a downregulation of the inflammatory response (10). Source: Recombinant protein corresponding to aa20-196, Gln20-Thr196, from human PILR-alpha, fused to 6xHis-Tag at C-terminal, NS0-derived. Molecular Weight: ~33-40kD Endotoxin: <0.10EU/1ug (LAL method) Biological Activity: Measured by its binding ability in a functional ELISA. When recombinant human PANP Fc Chimera is immobilized at 5ug/ml (100ul/well), the concentration of Recombinant Human PILR-alpha that produces 50% optimal binding response is approximately 0.4-2ug/ml. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute in sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved